Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05759221
Other study ID # 5279
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 20, 2022
Est. completion date March 31, 2024

Study information

Verified date April 2024
Source Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Airway involvement in sarcoidosis was demonstrated in a meaningful, albeit variable, proportion of patients through biopsy of the central, endoscopically visible airways. Ideally, biopsy of peripheral airways, nowadays possible with the introduction in the market of ultrathin bronchoscopes, might be associated with an increased diagnostic yield for the detection of granulomas.


Description:

Sarcoidosis is a systemic disorder of unknown cause that primarily involves the lung and lymphatic systems and that is more reliably diagnosed if a compatible clinical picture is combined with a pathologic demonstration of non-necrotizing epithelioid-cell granulomas. Endobronchial biopsy (EBB), taken from the central airways with standard-sized videobronchoscopes, has long been used in clinical practice, although its diagnostic yield has been shown to be widely variable across different ethnicities. A recent prospective study shows that the diagnostic yield of EBB in a sarcoidosis population with large prevalence of white Europeans is 37% overall, and 22% in patients who do not have endobronchial abnormalities. The diagnostic yield of biopsies taken from peripheral airways with ultrathin bronchoscopes was never been evaluated, to our knowledge.


Recruitment information / eligibility

Status Completed
Enrollment 79
Est. completion date March 31, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Necessity of a pathological confirmation of the clinical and radiological (CT) diagnosis of sarcoidosis. - Age >18 years - American Society of Anesthesiologists score 1-3. Exclusion Criteria: - Inability of unwillingness to consent - Steroid therapy (at least 1 week) in the 2 months preceding bronchoscopy. - Pregnancy. - Uncontrolled coagulopathy - Contraindication to the temporary interruption of anticoagulants or antiplatelet drugs, except aspirin.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Bronchoscopy with airway biopsy
Forceps biopsy of peripheral airways under direct endoscopic visualisation.

Locations

Country Name City State
Italy Fondazione Policlinico Univeristario A. Gemelli IRCCS Roma

Sponsors (1)

Lead Sponsor Collaborator
Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnostic yield of peripheral airway biopsy for the detection of granulomas The diagnostic yield will be calculated on a per patient basis (number of patients in whom the pathological examination of peripheral airway biopsy shows non necrotizing granulomas/all the patients submitted to the sampling procedure). 1 month
Secondary Complication rate Incidence of early complications 1 day
Secondary Diagnostic yield for the detection of endobronchial granulomas according to sex The association between the sex (male vs female) and the diagnostic yield of peripheral airway biopsy will be assessed 6 months
Secondary Diagnostic yield for the detection of endobronchial granulomas according to the ethnicity The association between the ethnicity (white versus other) and the diagnostic yield of peripheral airway biopsy will be assessed 6 months
Secondary Diagnostic yield for the detection of endobronchial granulomas according to the history of malignancy The association between a history of malignancy (presence versus absence of any malignancy diagnosed within 5 years of the procedure) and the diagnostic yield of peripheral airway biopsy will be assessed 6 months
Secondary Diagnostic yield for the detection of endobronchial granulomas according to the sarcoidosis stage The association between the sarcoidosis stage at CT (I vs II vs II vs IV) and the diagnostic yield of peripheral airway biopsy will be assessed 6 months
Secondary Diagnostic yield for the detection of endobronchial granulomas according to the presence of large airway mucosal abnormalities The association between the presence of endoscopically visible large airway abnormalities and the diagnostic yield of peripheral airway biopsy will be assessed 6 months
See also
  Status Clinical Trial Phase
Completed NCT04020380 - Azithromycin a Treatment for Pulmonary Sarcoidosis Phase 2
Recruiting NCT03260556 - Pirfenidone for Progressive Fibrotic Sarcoidosis Phase 4
Completed NCT03336736 - The Role of Physical Activity and Diet Within Pulmonary Sarcoidosis
Completed NCT03140644 - SARCOLOWDOSE : Ultra-low Dose CT Scan and MRI in Thoracic Sarcoidosis N/A
Completed NCT03793439 - Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis Phase 1
Recruiting NCT04895111 - Endobronchial Ultrasound Strain Elastography in Sarcoidosis
Not yet recruiting NCT05910554 - Investigation of the Efficacy of Metformin Therapy on Pulmonary Sarcoidosis Phase 2
Recruiting NCT05374447 - Diagnostic Yield of Intranodal Forceps Biopsies in Mediastinal Adenopathy N/A
Active, not recruiting NCT04314193 - Effectiveness of Methotrexate Versus Prednisolone as First-line Therapy for Pulmonary Sarcoidosis Phase 4
Completed NCT03727451 - A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis Phase 2
Recruiting NCT05746039 - Feasibility of Semaglutide in Advanced Lung Disease Phase 1/Phase 2
Completed NCT04803617 - Investigation of Pectoralis Muscle Strength in Elderly With Interstitial Lung Disease
Recruiting NCT03145922 - Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis
Completed NCT00279708 - Atorvastatin to Treat Pulmonary Sarcoidosis Phase 2
Recruiting NCT05567133 - Risk Indicators of Sarcoidosis Evolution-Unified Protocol
Not yet recruiting NCT05291468 - the PHENOSAR Trial: Use of Antibiotics in Treatment of Sarcoidosis N/A
Completed NCT05311150 - An RCT of NBI vs. White Light Guided Endobronchial Biopsy in Suspected Sarcoidosis N/A
Completed NCT05811962 - The Diagnostic and Prognostic Role of SAA in Intrathoracic Sarcoidosis
Completed NCT03320070 - Acthar Gel in Participants With Pulmonary Sarcoidosis Phase 4
Completed NCT03324503 - A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis N/A